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Further progress in the search for more effective but
safe antithrombotic agents is coupled to an improved
understanding of the factors involved in arterial and
venous thrombogenesis. Although arterial thrombosis is
initiated by formation of a layer of platelets on modified
endothelium or subendothelial constituents and subse-
quent recruitment of passing-by platelets, this phenom-
enon is not sufficient to lead to a full thrombus. Further
growth of such a platelet mass depends, to a large extent,
Nonactivation of Platelets in the
Normal Circulation
Platelets are versatile fragments of membrane-enclosed
cytoplasm that travel as single elements in the bloodstream.
Although sticky, they do not adhere to the normal intact
endothelial surface of vessel walls. Even after removal of
endothelium, the exposed basement membrane is hardly
reactive to platelets. Deeper located structures such as fi-
brillar collagen (particularly types I and III), elastin and
microfibrils, when exposed, become covered with platelets,
but soon gain the property of nonreactiveness to further
platelet deposition. When these platelets are progressively
detached from the denuded subendothelium, the surface still
remains nonthrombogenic as is the neointima that forms
after deendothelialization. However, if this neointima is
damaged a second time, microthrombi rapidly form, par-
ticularly when injured smooth muscle cells are exposed (1,2).
It is difficult to explain why platelets do not adhere to
normal endothelium. One explanation is that both platelets
and endothelium have a negative electrical charge and,
therefore, would be mutually repulsive (3). A second hy-
pothesis states that the platelet repulsion is an active process,
involving continuous synthesis by cells of prostacyclin (4).
However, this hypothesis does not explain why endothelium
treated with aspirin does not induce platelet adhesion (5).
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on the presence of free thrombin. Thrombin is mainly
generated by activation of factor XI on the platelet con-
tact with collagen. In addition, thrombin leads to for-
mation of fibrin, which maintains the stability of the
arterial platelet thrombus and is the main component of
the venous thrombus. The search for agents that inhibit
platelet activation and thrombin formation is, therefore,
a logical endeavor.
(1 Am Coli CardioI1986;8:2B-9B)
Moreover, repeated stimulation of endothelial cells in vivo
(6) and in tissue culture results in rapid refractoriness of
prostacyclin release. A third hypothesis suggests the con-
tinuous synthesis by endothelium of a chemorepellent
Iipoxygenase metabolite coded LOX (7).
Obviously, there is no satisfactory answer to the simple
question: Why do platelets remain apparently indifferent to
the vessel wall in the arterial circulation with its high pres-
sure system, to the intimate contact with the vessel structures
in the microcirculation and to the slow flow conditions in
veins?
Platelet Adhesion as the Initial Step in
Thrombus Formation
One of the first events in the thrombotic process is the
adherence of platelets to modified or injured endothelial
cells (Fig. 1). This is a complex process that involves struc-
tures of the subendothelium, physical factors, plasma pro-
teins and platelet receptors.
Subendothelium. Among the constituents of normal
subendothelium, the various types of collagen and its ubi-
quitous companion fibronectin are the most active toward
platelets. Platelet adhesion occurs more readily to collagen
structures that lie deep within vascular tissues (such as in
an ulcerated atherosclerotic plaque) than to those that are
found immediately beneath the endothelium (8,9).
Physical factors. An increase in shear rate will cause,
up to a certain value, more pronounced platelet adhesion.
Furthermore, adherence is linearly related to the platelet
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Figure 1. Phases of arterial thrombus formation. Scheme of mi-
croscopic events. ADP = adenosine diphosphate. (Reprinted with
permission from Fuster V, Chesebro JH [8].)
in platelets is also involved in the factor VIII/von Wille-
brand-mediated process; raising the cyclic AMP level impedes
adhesion.
On artificial surfaces. the process of platelet adhesion
is less well understood. A film of adsorbed plasma proteins
forms immediately after exposure of the surface to blood,
and apparently different surfaces become coated with dif-
ferent proteins that, by means of their surface charge, react
differently with platelets (13). Among the adsorbed plasma
proteins that have been studied are fibrinogen, which tends
to increase adherence, and albumin, which tends to have
the opposite effect.
Shape Change and Platelet Aggregation
Attachment of platelets to surfaces (adhesion) precedes
attachment of platelets to each other (aggregation) (Fig. I).
These two phenomena are separate, although it is difficult
to study them independently.
Platelet membrane receptors. There are several spe-
cific receptors on the platelet membrane. On formation of
an activator (see below) and receptor complex, a signal is
transferred to the interior of the cell (Fig. 4). Most agonists
seem to act by means of a common pathway, namely, the
hydrolysis of polyphosphatidyl-inositol into diacylglycerol
and inositol triphosphate, the latter being responsible for
calcium mobilization. Such cytoplasmic increase in calcium
is responsible for I) the contraction of the platelet, 2) the
secretion of its constituents (ADP and serotonin), and 3)
the activation of the membrane phospholipases and the
Figure 2. Binding of adhesive macromolecules (von Willebrand
factor [vWF] and fibrinogen) to platelet membrane glycoproteins.
Both macromolecules are enlarged compared with platelets. Fi-
brinogen binds to the glycoprotein lIb-glycoprotein II1a-Ca + +
complex, which is formed in presence of adenosine diphosphate
(ADP) derived from exogenous sources or secreted from platelet
storage granules. von Willebrand factor can either bind to gly-
coprotein Ib in absence of ADP or to the glycoprotein lIb-gly-
coprotein II1a-Ca + + complex in the presence of ADP. (Reprinted
with permission from Hawiger J, Kloczewiak, Timmons S. Plate-
let-receptor mechanisms for adhesive macromolecules. In: Oates
JA, Hawiger J, Ross R, eds. Interaction of Platelets With the
Vessel Wall. Bethesda: American Physiological Society, 1985: 1-19.
number, is increased in a constant flow system as compared
with a pulsatile one, is dependent on viscosity and is strik-
ingly enhanced by the presence of red blood cells. The latter
effect is partly due to the fact that in the flowing blood, red
cells occupy a central position and push the platelets toward
the periphery and, thus, increase platelet-vessel wall con-
tact. Blood turbulence at the branching points or in the
vicinity of a vessel injury may also release adenosine di-
phosphate (ADP) from red cells, ADP stimulates the ad-
herence of platelets.
Plasma proteins. A large multimeric protein termed
factor VIII/von Willebrand factor binds to the subendo-
thelium and gives rise to platelet adherence.
Platelet receptors. On their surface, platelets have gly-
coproteins. and one of them (glycoprotein Ib) plays a part
in the adhesive process to subendothelium (Fig. 2 and 3)
(l0, 11). The deficiency of this protein, as in the bleeding
disorder Bernard-Soulier syndrome, or antibodies against
this glycoprotein, prevents the adhesion of platelets to dam-
aged vascular endothelium (12). The balance between free
calcium ions and cyclic adenosine monophosphate (AMP)
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Figure 3. Orientation of glycoproteins Iba, Ibf3, IIba, IIbf3 and
IlIa on platelet plasma membrane. A calcium-dependent protease
(COP) hydrolyzes glycoprotein Iba, producing glycocalicin, and
trypsin produces macroglycopeptide as indicated. Ristocetin bridges
the interaction of factor (F) VIII: von Willebrand (vW) factor with
glycoprotein Ib (absent in Bernard-Soulier syndrome). Glycopro-
teins lIb and IlIa (defective in thrombasthenia) interact with fi-
brinogen after platelet activation. S = disulfide bond. (Reprinted
with permission from Verstraete M, Vermylen J [20].)
arachidonate pathway with synthesis and secretion of throm-
boxane Az (Fig. 4).
Platelet contraction. Specifically, after activation,
platelets are transformed from discs into spiny spheres: there
is a centripetal movement of the circumferential band of
microtubules forcing the granules towards the center of the
cell. As mentioned, such a contraction, as in most if not
all cells, is due to a cytoplasmic increase in calcium, an
activation of myosin light chain kinase through calmodulin
and interaction of phosphorylated myosin with actin.
Platelet aggregation. During the process of platelet ac-
tivation, ADP is released and is a potent inducer of platelet
aggregation, provided divalent calcium and intact fibrinogen
are present. As a first step, ADP binds to a specific receptor,
independent of calcium ions, and induces the shape change
of the platelets. This reaction leads to exposure of fibrinogen
binding sites on the platelets and depends on divalent cat-
ions. Fibrinogen then binds to its receptors on adjacent
platelets, thereby forming bridges between these cells that
are the key factors in establishing platelet aggregation.
Synthesis of thromboxane Az. Part of the platelet cal-
cium made available during activation seems to activate
platelet membrane phospholipases, which catalyze the lib-
eration of arachidonic acid. This polyunsaturated fatty acid
is then converted into cyclic endoperoxides by means of the
cyclooxygenase enzyme; the latter is transformed into
thromboxane A2 by means of the thromboxane synthetase
enzyme. Similar to the release of ADP, the synthesis and
release of thromboxane A2 activates the surface membrane
of neighboring platelets, resulting in an increase in cyto-
plasmic calcium and, therefore, in further release of ADP
and "stickiness" or aggregation of platelets.
Extrinsic activation of platelet activation. In patho-
logic situations such as when an atherosclerotic plaque rup-
tures, there are extrinsic activators that may be much more
potent in independently triggering calcium release and plate-
let aggregation than the physiologic low concentration of
ADP and thromboxane A2 (14-16). These are the already
mentioned exposed collagen from the vessel wall and throm-
bin resulting from the activation of the intrinsic and extrinsic
coagulation systems, large amounts of ADP released from
erythrocytes (hemorrhage with lysis) and presumably plate-
let-activating factor released from the neighboring cells (for
example, endothelial cells). These powerful extrinsic ag-
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Figure 4, Membrane receptors of the
arachidonic acid-dependent and inde-
pendent pathways, leading to mobili-
zation of Ca j- j- from storage sites and
its cyclic nucleotide-dependent inhibi-
tion. AMP = adenosine monophos-
phate; ATP = adenosine triphosphate;
PGG2 and PGH2 = prostacyclin G2 and
H2, respectively; i, i i and iii
= increased availability of calcium.
(Reprinted with permission from Ver-
straete M, Vermylen J [201.)
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gregating factors may, in part, explain why platelet inhibitor
drugs may be inefficient in preventing some arterial throm-
botic phenomena (16).
Secretion of Platelet Granules
Platelets contain three types of secretory granules, which
are listed in Table 1. Besides being extruded from the plate-
let at different sites, the quantitative response of the various
granules to stimuli differs. Alpha granule release is induced
by lower concentrations of stimuli than are required for
secretion of dense body constituents, which could imply a
difference in the energy requirement for release from the
two kinds of granules.
Thrombin causes the alpha granules to fuse with each
other and with elements of the surface-connected canalicular
system. Platelet factor IV and beta-thromboglobulin are te-
tramers of basic peptides present in alpha granules, which,
after activation of platelets, are released in the bloodstream.
Normal plasma does not contain measurable levels of these
proteins so that their presence in plasma is a marker of
platelet activation and secretion (17).
ADP is released by platelets in quantities sufficient to
induce aggregation. Thus, it is apparent that secretion of
dense body contents is an important feedback mechanism
for promoting growth of the platelet thrombus.
Activation of the Clotting Mechanism: Role
of Thrombin and Fibrin Formation
Table 1. Content of Platelet Granules
Dense granules
5-Hydroxytryptamine (serotonm). ADP. ATP, calcium
Alpha granules
Proteins not present m plasma: platelet factor IV, beta-thromboglobulin,
platelet derived growth factor
Proteins present in plasma' fibrinogen, fibronectin. von Willebrand fac-
tor, albumm, factor V, thrombospondin
Lysosomes
Acid hydrolase,
Cathepsm D. E
Peroxysome,
Catalase
During the process of platelet adhesion and aggregation,
the clotting mechanism may be activated and thrombin gen-
erated; this further promotes platelet aggregation and, most
importantly, leads to formation and polymerization of fibrin,
which stabilizes the platelet mass and allows the arterial
thrombus to resist the high intravascular pressure (Fig. 1).
Formation of fibrin. As discussed in more detail in this
symposium by Wessler and Gitel (18), the formation of
thrombin is the end point of a chain of enzymatic reactions
in which a proenzyme is activated to an enzyme, which in
tum activates another proenzyme and so on (Fig. 5). These
proenzymes (clotting factors) are present in the fluid phase
of blood; their level is very low. Their interaction is mark-
68 VERMYLEN ET AL
PLATELET AND FIBRIN ACTIVATION
INTRINSIC ACTIVATION
lACC Vol. 8. No.6
December 1986.2B-9B
negatively
charged surface
activation EXTRINSIC ACTIVATION
-/ factor XII 7
'\
factor XII a ,collagen platelets
" "' .....
',,~/
factor XI factor Xla
I
I Ca++y
factor IX --...-1 factor IXa
'actor VIII
factor X
phospholipids
Ca++
---- transformation
_______ activatIon
factor Xa
factor V
prothrombin
phospholipids
- Ca++
factor VII
j
tissue
___ --- thromioPlastin
.---------, :
factor VII a I
factor X :
phospholipids J
Ca ++
thrombin
Ca++
factor XIII factor
t
protrombln thrombin
I
I
I
I
t
fibrinogen fibnn monomer unstable polymer
"".----\
stable polymer
Figure 5. Mechanisms of clotting factor interactions. Coagulation
is initiated by either an intrinsic or extrinsic pathway. In the in-
trinsic pathway, the phospholipid is furnished by platelets. In the
extrinsic system, the phospholipid portion of tissue thromboplastin
functions on the activation of factor X. From factor Xa on, both
pathways converge on a common path. Omitted from the diagram
are inhibitors of the various steps, the augmentation of action of
each pathway by activated factors and the interaction between the
intrinsic and extrinsic systems. (Reprinted with permission from
Verstraete M, Vermylen J [20].)
edly enhanced by their being adsorbed and concentrated on
surfaces. Blood coagulation, therefore, can be considered
a series of surface-catalyzed events. For the clotting process
in vivo, the platelets would be a major supplier of these
surfaces. The chain of reaction is viewed as an amplification
system, allowing activation of a few molecules at the outset
to result in an explosive generation of thrombin (19).
Intrinsic versus extrinsic pathways of activation. Tra-
ditionally, a division is made between the "intrinsic" and
"extrinsic" pathways of activation (Fig. 5) (20). In the
intrinsic pathway, all necessary factors are present in the
circulating blood with a negatively charged surface (for
example, subendothelial collagen) or with a foreign surface
(for example, the glass wall of a test tube). In the extrinsic
activation pathway, it is not a plasma component but tissue
fluid that initiates the blood coagulation process; after vessel
damage this tissue factor, called tissue thromboplastin, mixes
with the blood and starts the coagulation process. After
activation of factor X, the two pathways merge into one.
In addition, both appear to be equally necessary to ensure
normal hemostasis.
Mechanisms of clotting factor interactions (Fig. 6).
More specifically, in the intrinsic pathway, coagulation is
initiated by the adsorption of factor XII onto a foreign sur-
face or collagen. Both kallikrein and high molecular weight
kininogen are required for the rapid surface activation of
factor XII. In addition, high molecular weight kininogen
increases the reactivity of factor XIIa in the conversion of
factor XI to XIa. Factor XIa converts factor IX to the active
protease factor IXa, whereupon factors VIII and IXa form
a complex, activating factor X. Both platelet phospholipid,
made available by aggregated platelets, and calcium (Ca2 +)
are essential for maximal activation of factor X. In the
presence of factor V, calcium and platelet phospholipid,
factor Xa subsequently converts prothrombin (factor II) to
thrombin. The extrinsic pathway is triggered by the release
of the tissue thromboplastin, a protein-phospholipid mixture
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Figure 6. In the intrinsic pathway of
coagulation, contact activation refers to
a series of reactions following adsorp-
tion of factor XII and XI as well as
prekallikrein and high molecular weight
kininogen (HMWK) to highly nega-
tively charged surfaces. The contact ac-
tivation does not require calcium and
results in surface-mediated conforma-
tional changes of the molecules. A to D
= sequence of events. S = disulfide
bond; SER = serotonin. (Reprinted with
permission from Verstraete M, Ver-
mylen J [20J.)
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that activates factor VII to VIla. Together they serve as
cofactors for the activation of both factor IX and factor X.
Once factor Xa is formed, thrombin production proceeds as
described. Thrombin cleaves fibrinogen to fibrin, activates
factor XIII, which stabilizes fibrin and also, as previously
mentioned, induces platelet aggregation.
Endogenous Inhibitors of Thrombus
Formation: The Role of Prostacyclin, Protein
C, Fibrinolysis and Antithrombin III
During platelet activation and fibrin formation there are
endogenous mechanisms that tend to limit thrombus for-
Figure 7. Protein C can be activated by thrombin, and this reaction
is greatly accelerated by a protein that is present on the endothelial
cell surface (this cofactor has been termed thrombomodulin). Protein
C inhibits activated factors Va and VIIIa and initiates fibrinolysis.
The inhibition of factors Va and VIIIa is also enhanced by another
vitamin K-dependent moiety, protein S. (Reprinted with permission
from Wessler S, et al. Warfarin: from bedside to bench. N Engl J
Med 1984;311:645-52.)
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mation. The four mechanisms that appear to be most im-
portant are the generation of prostacyclin, the activation of
protein C, fibrinolysis and the presence of antithrombin III.
Generation of prostacyclin. Prostacyclin, a compound
discovered by Moncada et al. (22), seems to be the main
prostaglandin metabolite in vascular tissue. It is most highly
concentrated on the intimal surface, particularly the endo-
thelium, and progressively decreases in activity toward the
adventitial surface. Prostacyclin is a potent systemic vaso-
dilator and, most importantly, is the most potent inhibitor
of platelet aggregation yet discovered. The platelet-inhibi-
tory action of prostacyclin is related to an activation of the
platelet membrane adenylate cyclase enzyme, which leads
to an increase in platelet cyclic adenosine 5'-monophosphate
and a decrease in platelet-free calcium and, therefore, in
platelet susceptibility to activation. Similar to the synthesis
of the prostanoid thromboxane A2 by the platelet (as pre-
viously discussed), the vessel wall synthesizes prostacyclin
from its own precursors. That is, arachidonic acid is con-
verted into cyclic endoperoxides by means of cyclooxygen-
ase enzyme, and such endoperoxides are subsequently con-
verted into prostacyclin by means of prostacyclin synthetase
enzyme. It has been shown that prostacyclin can be produced
by the cells of the vessel wall in response to stimulation by
endothelial injury or thrombin; most importantly, the plate-
lets adhering to sites of vascular damage not only release
thromboxane A2 , which promotes the concomitant aggre-
gation of platelets and release of endoperoxides, which po-
tentiate prostacyclin synthesis by the arterial wall. Thus,
the process of platelet aggregation and thrombosis may tend
to be limited or prevented.
In this context, Greenland Eskimos, who have a bleeding
tendency but in whom thrombosis or atherosclerosis does
not develop, seem to have little platelet thromboxane Az
and a substantial amount of a prostacyclin-type substance
(prostaglandin 13), all of these substances presumably related
to diet (23,24). Indeed, it has been suggested that an im-
balance between platelet proaggregating and disaggregating
activity of both prostaglandin systems (thromboxane Az and
prostacyclin) may be an important factor leading to throm-
bosis and vascular disease (25). Thus, it has been postulated
that certain of the so-called risk factors of atherosclerosis
and thrombosis may promote vascular disease by altering
this thromboxane Az-prostacyclin equilibrium system (8).
Activation of protein C (Fig. 7). Thrombin associated
with its endothelial cofactor thrombomodulin has an addi-
tional essential role, that of transforming protein C to ac-
tivated protein C. Activated protein C limits thrombosis (by
destroying factors VIlla and Va) and initiates fibrinolysis
(that is, it makes available a substance that releases tissue-
derived plasminogen activator, which in turn converts plas-
minogen to plasmin) (Fig. 7). Plasmin cleaves fibrin into
soluble fragments and degrades fibrinogen into fibrin deg-
radation or split products (19). Patients who are congenitally
deficient in protein C are prone to thrombosis, an indication
of the importance of this protein (6). Also, recurrent throm-
bosis has been reported among persons with a low fibrin-
olytic response (27). Apart from protein C, fibrin in itself
favors the release of tissue plasminogen activator. Because
plasminogen binds to fibrin during fibrin formation and is
only active when such binding takes place, fibrinolysis oc-
curs only in the thrombus (28). In this manner, plasmin
generation proceeds within the thrombus, where it is pro-
tected from rapid inactivation by plasma alphaz-antiplasmin.
Presence of antithrombin III. In addition to prosta-
cyclin, protein C and fibrinolysis, which limit thrombosis,
intravascular coagulation is regulated by other naturally oc-
curring plasma inhibitors. The most important is antithrom-
bin III (29). In addition, the endothelial cell tends to bind
free thrombin by means of a cofactor that favors a thrombin-
antithrombin III complex (30). A deficiency in antithrombin
III is associated with thrombosis, evidence of the clinical
relevance of this control mechanism (31).
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